CL2011002643A1 - Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c. - Google Patents

Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c.

Info

Publication number
CL2011002643A1
CL2011002643A1 CL2011002643A CL2011002643A CL2011002643A1 CL 2011002643 A1 CL2011002643 A1 CL 2011002643A1 CL 2011002643 A CL2011002643 A CL 2011002643A CL 2011002643 A CL2011002643 A CL 2011002643A CL 2011002643 A1 CL2011002643 A1 CL 2011002643A1
Authority
CL
Chile
Prior art keywords
ritonavir
hepatitis
virus
kit
pharmaceutical composition
Prior art date
Application number
CL2011002643A
Other languages
English (en)
Inventor
Jonathan Q Tran
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2011002643A1 publication Critical patent/CL2011002643A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Procedimiento para incrementar la biodisponibilidad de un inhibidor de proteasa ns3/4a del virus de la hepatitis C que comprende la coadministración de un compuesto r7227 y ritonavir; composición farmacéutica que los comprende y kit.
CL2011002643A 2009-04-25 2011-10-24 Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c. CL2011002643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17272209P 2009-04-25 2009-04-25

Publications (1)

Publication Number Publication Date
CL2011002643A1 true CL2011002643A1 (es) 2012-05-25

Family

ID=42236685

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002643A CL2011002643A1 (es) 2009-04-25 2011-10-24 Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c.

Country Status (36)

Country Link
US (4) US20100272682A1 (es)
EP (1) EP2421527B1 (es)
JP (1) JP5523552B2 (es)
KR (1) KR101471238B1 (es)
CN (2) CN102413827A (es)
AR (1) AR076388A1 (es)
AU (1) AU2010240893B2 (es)
BR (1) BRPI1015147B1 (es)
CA (1) CA2758644C (es)
CL (1) CL2011002643A1 (es)
CO (1) CO6440593A2 (es)
CR (1) CR20110551A (es)
DK (1) DK2421527T3 (es)
EC (1) ECSP11011420A (es)
ES (1) ES2683736T3 (es)
HK (1) HK1215858A1 (es)
HR (1) HRP20181306T1 (es)
HU (1) HUE040182T2 (es)
IL (1) IL215620A (es)
LT (1) LT2421527T (es)
MA (1) MA33212B1 (es)
MX (2) MX2011011105A (es)
MY (1) MY169734A (es)
NZ (1) NZ595917A (es)
PE (1) PE20120638A1 (es)
PL (1) PL2421527T3 (es)
PT (1) PT2421527T (es)
RS (1) RS57501B1 (es)
RU (1) RU2591830C2 (es)
SG (1) SG175328A1 (es)
SI (1) SI2421527T1 (es)
TR (1) TR201809600T4 (es)
TW (1) TWI468160B (es)
UA (1) UA103801C2 (es)
WO (1) WO2010122087A1 (es)
ZA (1) ZA201107421B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110075019A (ko) * 2008-10-15 2011-07-05 인터뮨, 인크. 치료용 항바이러스성 펩티드
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
CA2863002A1 (en) 2012-01-11 2013-07-18 Abbvie Inc. Processes for making hcv protease inhibitors
JP2015522022A (ja) * 2012-06-27 2015-08-03 アッヴィ・インコーポレイテッド Ｈｃｖの処置に使用するためのａｂｔ−４５０およびリトナビルおよび例えばａｂｔ−０７２および／またはａｂｔ−３３３の併用処置
EP2903988A1 (en) 2012-10-08 2015-08-12 AbbVie Inc. Compounds useful for making hcv protease inhibitors
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
HUE044606T2 (hu) * 2014-05-01 2019-11-28 Eiger Biopharmaceuticals Inc A hepatitis delta vírusfertõzés kezelése
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1302468B1 (en) 1992-12-29 2008-12-17 Abbott Laboratories Processes and intermediates for manufacturing retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
IL141438A0 (en) 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
SK742003A3 (en) * 2000-07-21 2003-06-03 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
MXPA05005773A (es) 2002-12-16 2005-08-16 Boehringer Ingelheim Int Uso de una combinacion que contiene un inhibidor no nucleosido de transcriptasa inversa (nnrti) con un inhibidor de citocromo p450, tales como inhibidores de la proteasa.
CA2543696A1 (en) * 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment

Also Published As

Publication number Publication date
EP2421527B1 (en) 2018-06-13
HUE040182T2 (hu) 2019-02-28
ES2683736T3 (es) 2018-09-27
CA2758644A1 (en) 2010-10-28
RU2011142651A (ru) 2013-05-27
KR101471238B1 (ko) 2014-12-12
IL215620A0 (en) 2012-01-31
ZA201107421B (en) 2022-11-30
RU2591830C2 (ru) 2016-07-20
RS57501B1 (sr) 2018-10-31
DK2421527T3 (en) 2018-08-13
PE20120638A1 (es) 2012-05-26
ECSP11011420A (es) 2011-11-30
US20180318267A1 (en) 2018-11-08
HRP20181306T1 (hr) 2018-10-19
NZ595917A (en) 2014-02-28
MX2011011105A (es) 2011-11-18
MY169734A (en) 2019-05-14
CR20110551A (es) 2011-12-13
SG175328A1 (en) 2011-11-28
SI2421527T1 (sl) 2018-09-28
US20170119739A1 (en) 2017-05-04
TW201041582A (en) 2010-12-01
BRPI1015147B1 (pt) 2022-03-08
MX351185B (es) 2017-10-04
EP2421527A1 (en) 2012-02-29
KR20120014170A (ko) 2012-02-16
PT2421527T (pt) 2018-08-02
MA33212B1 (fr) 2012-04-02
CO6440593A2 (es) 2012-05-15
TR201809600T4 (tr) 2018-07-23
US20100272682A1 (en) 2010-10-28
PL2421527T3 (pl) 2018-10-31
CA2758644C (en) 2018-01-09
CN105233249A (zh) 2016-01-13
US20200230112A1 (en) 2020-07-23
JP2012524753A (ja) 2012-10-18
TWI468160B (zh) 2015-01-11
AU2010240893B2 (en) 2015-02-05
WO2010122087A1 (en) 2010-10-28
JP5523552B2 (ja) 2014-06-18
AR076388A1 (es) 2011-06-08
UA103801C2 (ru) 2013-11-25
AU2010240893A1 (en) 2011-11-03
LT2421527T (lt) 2018-09-10
US10918626B2 (en) 2021-02-16
CN102413827A (zh) 2012-04-11
BRPI1015147A2 (pt) 2018-01-30
IL215620A (en) 2015-10-29
HK1215858A1 (zh) 2016-09-23

Similar Documents

Publication Publication Date Title
CL2011002643A1 (es) Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c.
CO6501153A2 (es) Inhibidores macrociclicos de serina proteasa
CL2012000919A1 (es) Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c.
ECSP11011065A (es) Composición farmacéutica de un potente inhibidor de hcv para su administración oral
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
CL2011002377A1 (es) Compuestos derivados de heterociclos triciclicos fusionados de anillo antraceno y bifenileno, inhibidores de proteína ns5a del virus de hepatitis c (vhc); composicion farmaceutica que los comprende; y uso del compuesto en la preparacion de un medicamento util en el tratamiento de hepatitis c.
CR20120418A (es) Inhibidores de virus flaviviridae
CO6341565A2 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
MX2012000959A (es) Inhibidores de los virus flaviviridae.
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
MX2013000642A (es) Composiciones farmaceuticas.
UY28250A1 (es) Composiciones farmacéuticas para inhibidores de la proteasa del virus de la hepatitis c
ECSP13012791A (es) Inhibidores de serina proteasa de hepatitis c a base de macrocíclicos de fenantridina
CO6511251A2 (es) Compuestos quimicos
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
IN2012DN01855A (es)
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2013003229A1 (es) Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc.
MX346730B (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
CO2019005070A2 (es) Formulaciones farmacéuticas
CL2014001016A1 (es) Compuestos triciclicos condensados y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende; y su uso en el tratamiento de una infeccion viral.
BR112013028487A2 (pt) inibidores do vírus da hepatite c